CoChat

A reduced form of nicotinamide riboside defines a new path for NAD+ biosynthesis and acts as an orally bioavailable NAD+ precursor

Open access
Giroud-Gerbetant, Judith, Joffraud, Magali, Giner, Maria Pilar, Cercillieux, Angelique, Bartova, Simona, Makarov, Mikhail V., Zapata-Pérez, Rubén, Sánchez-García, José L., Houtkooper, Riekelt H., Migaud, Marie E., Moco, Sofia, Canto, Carles · 2019 · Molecular Metabolism
Cited by 129

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

A decay in intracellular NAD+ levels is one of the hallmarks of physiological decline in normal tissue functions. Accordingly, dietary supplementation with NAD+ precursors can prevent, alleviate, or even reverse multiple metabolic complications and age-related disorders in diverse model organisms. Within the constellation of NAD+ precursors, nicotinamide riboside (NR) has gained attention due to its potent NAD+ biosynthetic effects in vivo while lacking adverse clinical effects. Nevertheless, NR is not stable in circulation, and its utilization is rate-limited by the expression of nicotinamide riboside kinases (NRKs). Therefore, there is a strong interest in identifying new effective NAD+ precursors that can overcome these limitations. Through a combination of metabolomics and pharmacological approaches, we describe how NRH, a reduced form of NR, serves as a potent NAD+ precursor in mammalian cells and mice. NRH acts as a more potent and faster NAD+ precursor than NR in mammalian cells and tissues. Despite the minor structural difference, we found that NRH uses different steps and enzymes to synthesize NAD+, thus revealing a new NRK1-independent pathway for NAD+ synthesis. Finally, we provide evidence that NRH is orally bioavailable in mice and prevents cisplatin-induced acute kidney injury. Our data identify a new pathway for NAD+ synthesis and classify NRH as a promising new therapeutic strategy to enhance NAD+ levels.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.molmet.2019.09.013

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Research works printed but not linked: 22

  1. Chambon, 1963, Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme, Biochemical and Biophysical Research Communications, 1139
  2. Lee, 1991, ADP-ribosyl cyclase: an enzyme that cyclizes NAD+ into a calcium-mobilizing metabolite, Cell Regulation, 2, 203, 10.1091/mbc.2.3.203 · DOI · Paper page
  3. Belenky, 2007, NAD+ metabolism in health and disease, Trends in Biochemical Sciences, 32, 12, 10.1016/j.tibs.2006.11.006 · DOI · Paper page
  4. Benyo, 2005, GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing, Journal of Clinical Investigation, 115, 3634, 10.1172/JCI23626 · DOI · Paper page
  5. Soga, 2003, Molecular identification of nicotinic acid receptor, Biochemical and Biophysical Research Communications, 303, 364, 10.1016/S0006-291X(03)00342-5 · DOI · Paper page
  6. Tunaru, 2003, PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect, Nature Medicine, 9, 352, 10.1038/nm824 · DOI · Paper page
  7. Wise, 2003, Molecular identification of high and low affinity receptors for nicotinic acid, Journal of Biological Chemistry, 278, 9869, 10.1074/jbc.M210695200 · DOI · Paper page
  8. Yoshino, 2011, Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice, Cell Metabolism, 14, 528, 10.1016/j.cmet.2011.08.014 · DOI · Paper page
  9. Nikiforov, 2011, Pathways and subcellular compartmentation of NAD biosynthesis in human cells: from entry of extracellular precursors to mitochondrial NAD generation, Journal of Biological Chemistry, 286, 21767, 10.1074/jbc.M110.213298 · DOI · Paper page
  10. Dolopikou, 2019, Acute nicotinamide riboside supplementation improves redox homeostasis and exercise performance in old individuals: a double-blind cross-over study, European Journal of Nutrition
  11. Ramesh, 2014, Mouse models and methods for studying human disease, acute kidney injury (AKI), Methods in Molecular Biology, 1194421
  12. Wong, 2002, Identification of N1-methyl-2-pyridone-5-carboxamide and N1-methyl-4-pyridone-5-carboxamide as components in urine extracts of individuals consuming coffee, Journal of Pharmaceutical and Biomedical Analysis, 30, 773, 10.1016/S0731-7085(02)00384-9 · DOI
  13. Makarov, 2019, Syntheses and chemical properties of beta-nicotinamide riboside and its analogues and derivatives, Beilstein Journal of Organic Chemistry, 15401
  14. Tran, 2016, PGC1alpha drives NAD biosynthesis linking oxidative metabolism to renal protection, Nature, 531, 528, 10.1038/nature17184 · DOI · Paper page
  15. Poyan Mehr, 2018, De novo NAD+ biosynthetic impairment in acute kidney injury in humans, Nature Medicine, 24, 1351, 10.1038/s41591-018-0138-z · DOI · Paper page
  16. Ozkok, 2014, Pathophysiology of cisplatin-induced acute kidney injury, BioMed Research International, 2014967826
  17. Miller, 2010, Mechanisms of cisplatin nephrotoxicity, Toxins (Basel), 2, 2490, 10.3390/toxins2112490 · DOI · Paper page
  18. Mandic, 2003, Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling, Journal of Biological Chemistry, 278, 9100, 10.1074/jbc.M210284200 · DOI · Paper page
  19. Bottinger, 2002, TGF-beta signaling in renal disease, Journal of the American Society of Nephrology, 13, 2600, 10.1097/01.ASN.0000033611.79556.AE · DOI · Paper page
  20. Yang, 2019, Dihydronicotinamide riboside is a potent NAD+ concentration enhancer in vitro and in vivo, Journal of Biological Chemistry, 10.1074/jbc.RA118.005772 · DOI · Paper page
  21. Kulikova, 2015, Generation, release, and uptake of the NAD precursor nicotinic acid riboside by human cells, Journal of Biological Chemistry, 290, 27124, 10.1074/jbc.M115.664458 · DOI · Paper page
  22. Katsyuba, 2018, De novo NAD+ synthesis enhances mitochondrial function and improves health, Nature, 563, 354, 10.1038/s41586-018-0645-6 · DOI · Paper page

Cited by

See all 129

Metadata

Authors
Giroud-Gerbetant, J., Joffraud, M., Giner, M. P., Cercillieux, A., Bartova, S., Makarov, M. V., Zapata-Pérez, R., Sánchez-García, J. L., Houtkooper, R. H., Migaud, M. E., Moco, S., & Canto, C.
Venue
Molecular Metabolism
Publisher
Elsevier BV
Published
2019-12
Volume
30
Pages
192-202
ISSN
2212-8778 (ISSN-L)
OpenAlex
W2978252541
Cited by
129
References
19
FWCI
7.37
Type
journal article
Language
en
Open access
gold
Licence
Funders
  • National Institutes of Health (AT009908-01)
  • Fundación Séneca
  • Horizon 2020 Framework Programme
  • École Polytechnique Fédérale de Lausanne
  • Horizon 2020 (840110)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A reduced form of nicotinamide riboside defines a new path for NAD+ biosynthesis and acts as an orally bioavailable NAD+ precursor. https://app.cochat.ai/papers/10.1016/j.molmet.2019.09.013
The paper
Giroud-Gerbetant, J., Joffraud, M., Giner, M. P., Cercillieux, A., Bartova, S., Makarov, M. V., Zapata-Pérez, R., Sánchez-García, J. L., Houtkooper, R. H., Migaud, M. E., Moco, S., & Canto, C. (2019). A reduced form of nicotinamide riboside defines a new path for NAD+ biosynthesis and acts as an orally bioavailable NAD+ precursor. Molecular Metabolism. https://doi.org/10.1016/j.molmet.2019.09.013

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.